Table 2.
Some important miRNA mediated therapeutic approaches against thyroid cancer.
| Sl.No. | miRNAs | Used model | Therapeutics | Type of cancer | Reference |
|---|---|---|---|---|---|
| 1 | miRNA-101 and miRNA-145 | In vitro (TPC-1 cells and HTH83, 293T cells) | Tumor suppression | Thyroid Cancer | Paskaš et al. (2015); Wang et al. (2014) |
| 2 | miRNA-219-5p | In vitro (PTC cell line K1) | Tumor suppression | Thyroid Cancer | Huang et al. (2015) |
| 3 | miRNA-182 | PTC-derived thyroid cell lines, TPC-1 and BCPAP and Four-week-old male BALB/c nu/nu mice | Tumor suppression | Thyroid Cancer | Zhu et al. (2014) |
| 4 | miRNA-122 | WRO cells and in vivo xenograft model (4-week-old athymic nude mice) | Tumor suppression | Thyroid Cancer | Reddi et al. (2011) |
| 5 | Combination of cabozantinib and miRNA153-3p | Human MTC TT cell lines and mouse xenograft model (female athymic (nu/nu) mice (5–6 weeks old) | Tumor suppression | Thyroid Cancer | JooLJ et al., 2019 |
| 6 | miRNA-564 | TPC-1, BCPAP, and HTH83 and a normal human thyroid cell line (HT-ori3) & in vivo tumor xenograft model (BALB/c nude mice) | Tumor suppression | Thyroid Cancer | Song et al. (2019) |
| 7 | miRNA-204-5p | TCP-1 and BCPAP and HEK293T cell line and xeno-graft model (Male BALB/c nude mice (4–6 weeks of age) | Tumor suppression | Thyroid Cancer | Liu et al. (2015) |
| 8 | Cubosomes (lipid nanoparticles) loaded with miRNA-7-5p | Human glioblastoma-derived A172 (TMZ-sensitive) and T98G (TMZ-resistant) cell lines | Tumor suppression | Thyroid Cancer | Gajda et al. (2020) |